尼可地尔联合曲美他嗪治疗冠心病心绞痛患者的效果分析

Effect Analysis of Nicodil Combined with Trimetazidine in the Treatment of Patients with Coronary Heart Disease-Angina Pectorise

目的:探究尼可地尔联合曲美他嗪对冠心病心绞痛(CHD-AP)患者的治疗效果。方法:选取2021年10月—2023年2月莒县人民医院急诊科收治的78例CHD-AP患者为研究对象,按随机数字表法将其分为对照组和研究组,各39例。对照组给予尼可地尔片治疗,研究组在对照组基础上联合盐酸曲美他嗪片治疗。比较两组治疗总有效率、心绞痛发作情况、炎症指标和不良反应发生情况。结果:研究组治疗总有效率为92.31%,高于对照组的74.36%,差异有统计学意义(P<0.05)。治疗后,研究组心绞痛发作情况弱于对照组,且研究组心绞痛发作次数少于对照组,心绞痛持续时间短于对照组,差异均有统计学意义(P<0.05)。治疗后,两组肿瘤坏死因子-α、高敏C反应蛋白、白细胞介素-6、白细胞介素-8均低于治疗前,且研究组均低于对照组,差异均有统计学意义(P<0.05)。研究组不良反应发生率为15.38%,相较于对照组的7.69%,差异无统计学意义(P>0.05)。结论:尼可地尔联合曲美他嗪对CHD-AP患者的治疗效果显著,可有效减少心绞痛发作次数,缩短心绞痛持续时间,减少血清中的炎症物质,具有一定的安全性。

Objective:To explore the efficacy of Nicordil combined with Trimetazidine in the treatment of coronary heart disease-angina pectoris(CHD-AP).Methods:A total of 78 CHD-AP patients admitted to Department of Emergency Juxian County People’s Hospital from October 2021 to February 2023 were selected as the study objects.They were divided into a control group and a study group according to random number table method,with 39 cases in each group.The control group was treated with Nicodil Tablets,the Study group was treated with Trimetazidine Hydrochloride Tablets on the basis of t control group.The total effective rate,incidence of angina pectoris,inflammation indexes and the occurrence of adverse reactions were compared between the two groups.Results:The total effective rate of the study group was 92.31%,which was higher than 74.36%in the control group,the difference was statistically significant(P<0.05).After treatment,the frequency of angina pectoris in the study group was less than that in the control group,the duration of angina pectoris was shorter than that in the control group,with statistical significances(P<0.05).After treatment,the tumor necrosis factor-α,highly sensitive C-reactive protein,interleukin-6,interleukin-8 of the two groups were lower than before treatment,the study group were lower than those in the control group,with statistical significances(P<0.05).The incidence of adverse reactions in the study group was 15.38%,compared with 7.69%in the control group,the difference was not statistically significant(P>0.05).Conclusion:Nicordil combined with Trimetazidine is effective in the treatment of CHD-AP patients,which can effectively reduce the attack number of angina pectoris,shorten the duration of angina pectorts,reduce the inflammatory substances in serum,has certain safety.